The state of biotech M&A 2024

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Biotech M&A has been disappointing. Perhaps the trend will improve before we reach the holidays, but I can only opine on what’s transpired, and honestly, that’s not much.

By my count, there have been 35 transactions totaling $45 billion. My M&A list might differ from others, but I tried to capture all the meaningful activity, year to date.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Without federal oversight, nursing homes will put profit ahead of care

About 5% of Americans require skilled care at some point as they age. The horrific reports of more than 200,000 deaths of nursing home residents

July 26, 2024

Ford Motor Company F stock analysis & what to expect next with F stock

August 11, 2023

Authenticx Launches AI Models to Detect Reportable Events in Healthcare Conversations

What You Should Know: – Authenticx, a leader in conversational intelligence for healthcare launches new suite of AI models capable of detecting reportable events within

August 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.